v3.25.4
Stock-based Compensation
9 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation [Text Block]

18. Stock-based Compensation

Stock-based compensation expense was comprised of the following for the period ended:

    Three months ended December 31,     Nine months ended December 31,  
    2025     2024     2025     2024  
Stock options $ 22   $ 52   $ 86   $ 226  
RSUs   6,976     3,474     18,134     6,023  
Total $ 6,998   $ 3,526   $ 18,220   $ 6,249  

(a) Stock options

The Company has established a rolling Stock Option Plan (the "Plan").  Under the Plan, the number of shares reserved for issuance may not exceed 10% of the total number of issued and outstanding shares and, to any one optionee, may not exceed 5% of the issued shares on a yearly basis.  The maximum term of each option shall not be greater than 10 years.  The exercise price of each option shall not be less than the market price of the Company's shares at the date of grant.  Options granted to consultants performing investor relations activities shall vest over a minimum of 12 months with no more than a quarter of such options vesting in any 3 month period.  All other options vest at the discretion of the Board of Directors.

On April 1, 2024, the Company modified the exercise price from Canadian dollars to United States dollars of stock options that were held by employees in the United States of America and in Europe. The modification resulted in $nil additional stock-based compensation expense. 

Following is a summary of changes in stock options outstanding for stock options with a CAD exercise price:

    Outstanding    

Weighted average

exercise price - CAD

 
Balance, March 31, 2024   3,465,915   $ 5.24  
Change in exercise price   (1,605,015 )   (3.32 )
Balance, March 31, 2025   1,860,900   $ 6.89  
Exercised   (75,100 )   (5.98 )
Balance, December 31, 2025   1,785,800   $ 6.93  

 

Following is a summary of changes in stock options outstanding for stock options with a USD exercise price:

    Outstanding    

Weighted average

exercise price - USD

 
Balance, March 31, 2024   -   $ -  
Change in exercise price   1,605,015     2.62  
Expired   (54,615 )   (7.75 )
Exercised   (100,000 )   (1.09 )
Balance, March 31, 2025   1,450,400   $ 2.53  
Exercised   (600,000 )   (1.21 )
Balance, December 31, 2025   850,400   $ 3.47  

The stock options outstanding and exercisable with CAD exercise price as at December 31, 2025, are as follows:

  Outstanding     Exercisable     Exercise price - CAD     Expiry date  
                       
  2,000     2,000   $ 15.70     February 11. 2026  
  282,400     282,400     5.66     August 26, 2027  
  50,000     50,000     10.00     March 26, 2028  
  470,000     470,000     6.86     July 6, 2028  
  400,000     400,000     3.10     September 18, 2028  
  100,000     100,000     1.35     December 21, 2028  
  200,000     200,000     1.45     February 10, 2030  
  20,000     20,000     1.90     May 29, 2030  
  1,400     1,400     10.80     December 24, 2030  
  60,000     60,000     18.35     April 29, 2031  
  180,000     153,000     18.50     October 7, 2031  
  40,000     40,000     25.35     November 10, 2031  
  1,785,800     1,758,800              

The stock options outstanding and exercisable with USD exercise price as at December 31, 2025, are as follows:

  Outstanding     Exercisable     Exercise price - USD     Expiry date  
                       
  50,400     50,400   $ 4.36     August 26, 2027  
  500,000     500,000     1.23     September 14, 2027  
  130,000     130,000     5.14     July 6, 2028  
  100,000     100,000     1.09     February 10, 2030  
  30,000     30,000     20.03     April 6, 2031  
  20,000     -     20.36     November 10, 2031  
  20,000     20,000     16.61     December 9, 2031  
  850,400     830,400              

 

(b) Restricted share-units

The Company has established a Restricted Share Unit Plan (the “RSU Plan”).  Under the RSU Plan, together with any other share compensation arrangement, the number of shares reserved for issuance may not exceed 10% of the total number of issued and outstanding shares and, to any one optionee, may not exceed 5% of the issued shares on a yearly basis.  The Board may in its own discretion, at any time, and from time to time, grant RSUs to any employee, director or consultant of the Company or its subsidiaries (collectively, "Eligible Person"), other than persons conducting investor relations activities, from time to time by the Board, subject to the limitations set forth in the RSU Plan.  The Board may designate one or more performance periods under the RSU Plan.  In respect of each designated performance period and subject to the terms of the RSU Plan, the Board may from time to time establish the grant date and grant to any Eligible Person one or more RSUs as the Board deems appropriate. 

The fair value of restricted shares units (RSUs) is generally measured as the grant date price of the Company's share.

On April 17, 2025, the Company granted 2,797,000 RSU to certain employees, officers, directors and eligible consultants of the Company with a fair value of C$2.05 per share. From this RSU grant, 2,597,000  vest over a twelve month period and 200,000 RSU vest over a three year period.

On July 8, 2025, the Company granted 2,809,000 RSU to certain employees, officers, directors and eligible consultants of the Company with a fair value of C$3.03 per share and vesting on July 8, 2026.

On October 31, 2025, the Company granted 2,720,900 RSU to certain employees, officers, directors and eligible consultants of the Company with a fair value of C$7.30 per share and vesting on October 31, 2026.

Following is a summary of changes in restricted share units outstanding as of December 31, 2025:

    Outstanding  
       
Balance, March 31, 2024   1,379,056  
Granted   6,050,000  
Exercised   (326,644 )
Balance, March 31, 2025   7,102,412  
Granted   8,326,900  
Exercised   (1,846,882 )
Balance, December 31, 2025   13,582,430